3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Vascular Diseases
1
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pathologic Processes
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplastic Processes
1
Neoplasms, Plasma Cell
1
Neoplasms, Glandular and Epithelial
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lymphoid Interstitial Pneumonia
1
Lymphatic Diseases
1
Lung Neoplasms
1
Lung Diseases
1
Liver Neoplasms
1
Liver Diseases
1
Lip Neoplasms
1
Immunoproliferative Disorders
1
Hemorrhagic Disorders
1
Hematologic Diseases
1
Interventions
Bortezomib
5
Dexamethasone
4
Lenalidomide
3
Granulocyte Colony-Stimulating Factor
3
fludarabine
2
filanesib
2
dacetuzumab
2
Steroids
2
Injections, Subcutaneous
2
Filgrastim
2
plerixafor
1
ofatumumab
1
isatuximab
1
fludarabine phosphate
1
ficlatuzumab
1
birtamimab
1
Zoledronic Acid
1
Whole-Body Irradiation
1
Vorinostat
1
Tacrolimus
1
Rifaximin
1
Proteasome Inhibitors
1
Plasma Exchange
1
Mycophenolic Acid
1
KW-2478
1
Hsp90 inhibitor KU757
1
Erlotinib Hydrochloride
1
Denosumab
1
Cyclophosphamide
1
Calcium Dobesilate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Paraproteinemias
×
ficlatuzumab
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled